Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Breast cancer
Local recurrence
Local relapse
Lymph node
Recurrence
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
27
01
2023
accepted:
12
03
2023
medline:
15
5
2023
pubmed:
30
3
2023
entrez:
29
3
2023
Statut:
ppublish
Résumé
We aimed to determine the pattern of isolated local recurrences (ILR) in women with stage II-III hormone receptor-positive and human epidermal growth factor receptor 2 breast cancer (HR + /HER2-BC) after 10-year follow-up. UNICANCER-PACS 01 and PACS 04 trials included 5,008 women with T1-T3 and N1-N3 to evaluate the efficacy of different anthracycline ± taxanes-containing regimens after modified mastectomy or lumpectomy plus axillary lymph node dissection. We analyzed the data from 2,932 women with HR + /HER2- BC to evaluate the cumulative incidence of ILR and describe the factors associated with ILR. After a median follow-up of 9.1 years (95% CI 9.0-9.2 years), the cumulative incidence of ILR increased steadily between 1 and 10 years from 0.2% to 2.5%. The multivariable analysis showed that older age (subhazard ratios [sHR] = 0.95, 95% CI 0.92-0.99) and mastectomy (sHR = 0.39, 95% CI 0.17-0.86) were associated with lower risk of ILR, and no adjuvant endocrine therapy (sHR = 2.73, 95% CI 1.32 7-5.67) with increased risk of ILR. In this population of high-risk patients with localized HR + /HER2- BC, the risk of ILR was low but remained constant over 10 years. Younger age at diagnosis, breast-conserving surgery, and adjuvant endocrine therapy were independent risk factors of ILR.
Identifiants
pubmed: 36988749
doi: 10.1007/s10549-023-06912-4
pii: 10.1007/s10549-023-06912-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
371-379Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
DeSantis CE, Ma J, Gaudet MM et al (2019) Breast cancer statistics. CA Cancer J Clin 69:438–451. https://doi.org/10.3322/caac.21583
doi: 10.3322/caac.21583
pubmed: 31577379
Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 30:1194–1220. https://doi.org/10.1093/annonc/mdz173
doi: 10.1093/annonc/mdz173
pubmed: 31161190
van Dongen JA, Voogd AC, Fentiman IS et al (2000) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst 92:1143–1150. https://doi.org/10.1093/jnci/92.14.1143
doi: 10.1093/jnci/92.14.1143
pubmed: 10904087
Peng G, Zhou Z, Jiang M, Yang F (2019) Can a subgroup at high risk for LRR be identified from T1–2 breast cancer with negative lymph nodes after mastectomy? A meta-analysis. Biosci Rep. https://doi.org/10.1042/BSR20181853
Yang SH, Yang KH, Li YP et al (2008) Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 19:1039–1044. https://doi.org/10.1093/annonc/mdm573
doi: 10.1093/annonc/mdm573
pubmed: 18187486
Rouzier R, Extra JM, Carton M et al (2001) Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 19:3828–3835. https://doi.org/10.1200/JCO.2001.19.18.3828
doi: 10.1200/JCO.2001.19.18.3828
pubmed: 11559720
Hattangadi-Gluth JA, Wo JY, Nguyen PL et al (2012) Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys 82:1185–1191. https://doi.org/10.1016/j.ijrobp.2011.02.061
doi: 10.1016/j.ijrobp.2011.02.061
pubmed: 21601377
Zumsteg ZS, Morrow M, Arnold B et al (2013) Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1–2N0 triple-negative breast cancer. Ann Surg Oncol 20:3469–3476. https://doi.org/10.1245/s10434-013-3011-9
doi: 10.1245/s10434-013-3011-9
pubmed: 23686101
pmcid: 5730455
Lowery AJ, Kell MR, Glynn RW et al (2012) Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 133:831–841. https://doi.org/10.1007/s10549-011-1891-6
doi: 10.1007/s10549-011-1891-6
pubmed: 22147079
Wapnir IL, Price KN, Anderson SJ et al (2018) Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial. J Clin Oncol 36:1073–1079. https://doi.org/10.1200/JCO.2017.76.5719
doi: 10.1200/JCO.2017.76.5719
pubmed: 29443653
pmcid: 5891132
de Bock GH, van der Hage JA, Putter H et al (2006) Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European organisation for research and treatment of cancer studies. Eur J Cancer 42:351–356. https://doi.org/10.1016/j.ejca.2005.10.006
doi: 10.1016/j.ejca.2005.10.006
pubmed: 16314086
Kurtz JM, Amalric R, Brandone H et al (1989) Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer 63:1912–1917. https://doi.org/10.1002/1097-0142(19890515)63:10%3c1912::aid-cncr2820631007%3e3.0.co;2-y
doi: 10.1002/1097-0142(19890515)63:10<1912::aid-cncr2820631007>3.0.co;2-y
pubmed: 2702564
Fisher B, Anderson S, Redmond CK et al (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456–1461. https://doi.org/10.1056/NEJM199511303332203
doi: 10.1056/NEJM199511303332203
pubmed: 7477145
Wapnir IL, Anderson SJ, Mamounas EP et al (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. J Clin Oncol 24:2028–2037. https://doi.org/10.1200/JCO.2005.04.3273
doi: 10.1200/JCO.2005.04.3273
pubmed: 16648502
van Laar C, van der Sangen MJC, Poortmans PMP et al (2013) Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer 49:3093–3101. https://doi.org/10.1016/j.ejca.2013.05.030
doi: 10.1016/j.ejca.2013.05.030
pubmed: 23800672
Poortmans PMP, Arenas M, Livi L (2017) Over-irradiation. Breast 31:295–302. https://doi.org/10.1016/j.breast.2016.07.022
doi: 10.1016/j.breast.2016.07.022
pubmed: 27522160
Roché H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. JCO 24:5664–5671. https://doi.org/10.1200/JCO.2006.07.3916
doi: 10.1200/JCO.2006.07.3916
Spielmann M, Roché H, Delozier T et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129–6134. https://doi.org/10.1200/JCO.2009.23.0946
doi: 10.1200/JCO.2009.23.0946
pubmed: 19917839
Moossdorff M, van Roozendaal LM, Strobbe LJA et al (2014) Maastricht delphi consensus on event definitions for classification of recurrence in breast cancer research. JNCI: J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju288
doi: 10.1093/jnci/dju288
pubmed: 25381395
pmcid: 4357796
Elkhuizen PH, van de Vijver MJ, Hermans J et al (1998) Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 40:859–867. https://doi.org/10.1016/s0360-3016(97)00917-6
doi: 10.1016/s0360-3016(97)00917-6
pubmed: 9531371
Elkhuizen PH, Hermans J, Leer JW, van dE Vijver MJ (2001) Isolated late local recurrences with high mitotic count and early local recurrences following breast-conserving therapy are associated with increased risk on distant metastasis. Int J Radiat Oncol Biol Phys 50:387–396. https://doi.org/10.1016/s0360-3016(01)01469-9
doi: 10.1016/s0360-3016(01)01469-9
pubmed: 11380225
Melvin JC, Purushotham AD, Garmo H et al (2016) Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time. Br J Cancer 114:88–95. https://doi.org/10.1038/bjc.2015.314
doi: 10.1038/bjc.2015.314
pubmed: 26657655
Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378. https://doi.org/10.1200/JCO.2007.14.4287
doi: 10.1200/JCO.2007.14.4287
pubmed: 18413639
Arvold ND, Taghian AG, Niemierko A et al (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29:3885–3891. https://doi.org/10.1200/JCO.2011.36.1105
doi: 10.1200/JCO.2011.36.1105
pubmed: 21900114
pmcid: 3189090
Dominici LS, Mittendorf EA, Wang X et al (2012) Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res 14:R82. https://doi.org/10.1186/bcr3197
doi: 10.1186/bcr3197
pubmed: 22621306
pmcid: 3446345
Moo T-A, McMillan R, Lee M et al (2014) Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1–T2 breast cancer and 1–3 positive lymph nodes. Ann Surg Oncol 21:1569–1574. https://doi.org/10.1245/s10434-014-3488-x
doi: 10.1245/s10434-014-3488-x
pubmed: 24488216
pmcid: 4366059
Fisher B, Bryant J, Dignam JJ et al (2002) Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141–4149. https://doi.org/10.1200/JCO.2002.11.101
doi: 10.1200/JCO.2002.11.101
pubmed: 12377957
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1716. https://doi.org/10.1016/S0140-6736(11)61629-2
doi: 10.1016/S0140-6736(11)61629-2
Fitzal F, Filipits M, Rudas M et al (2015) The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer 112:1405–1410. https://doi.org/10.1038/bjc.2015.98
doi: 10.1038/bjc.2015.98
pubmed: 25867274
pmcid: 4402462
Colleoni M, Sun Z, Price KN et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol 34:927–935. https://doi.org/10.1200/JCO.2015.62.3504
doi: 10.1200/JCO.2015.62.3504
pubmed: 26786933
pmcid: 4933127
Voogd AC, Nielsen M, Peterse JL et al (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19:1688–1697. https://doi.org/10.1200/JCO.2001.19.6.1688
doi: 10.1200/JCO.2001.19.6.1688
pubmed: 11250998
Han W, Kim SW, Ae Park I et al (2004) Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4:82. https://doi.org/10.1186/1471-2407-4-82
doi: 10.1186/1471-2407-4-82
pubmed: 15546499
pmcid: 545947
De La Cruz L, Blankenship SA, Chatterjee A et al (2016) Outcomes after oncoplastic breast-conserving surgery in breast cancer patients: a systematic literature review. Ann Surg Oncol 23:3247–3258. https://doi.org/10.1245/s10434-016-5313-1
doi: 10.1245/s10434-016-5313-1
pubmed: 27357177
Moran MS, Schnitt SJ, Giuliano AE et al (2014) Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32:1507–1515. https://doi.org/10.1200/JCO.2013.53.3935
doi: 10.1200/JCO.2013.53.3935
pubmed: 24516019
Fisher B, Redmond C, Poisson R et al (1989) Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320:822–828. https://doi.org/10.1056/NEJM198903303201302
doi: 10.1056/NEJM198903303201302
pubmed: 2927449
Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241. https://doi.org/10.1056/NEJMoa022152
doi: 10.1056/NEJMoa022152
pubmed: 12393820
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0
doi: 10.1016/S0140-6736(05)66544-0
Blamey RW, Bates T, Chetty U et al (2013) Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 49:2294–2302. https://doi.org/10.1016/j.ejca.2013.02.031
doi: 10.1016/j.ejca.2013.02.031
pubmed: 23523089
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352. https://doi.org/10.1016/S0140-6736(15)61074-1
doi: 10.1016/S0140-6736(15)61074-1
Pistilli B, Paci A, Ferreira AR et al (2020) Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol 38:2762–2772. https://doi.org/10.1200/JCO.19.01758
doi: 10.1200/JCO.19.01758
pubmed: 32568632
pmcid: 7430219
Rassy E, Bardet A, Bougacha O et al (2022) Association of adherence to endocrine therapy among patients with breast cancer and potential drug-drug interactions. JAMA Netw Open. https://doi.org/10.1001/jamanetworkopen.2022.44849
doi: 10.1001/jamanetworkopen.2022.44849
pubmed: 36459136
pmcid: 9719053
Miles RC, Gullerud RE, Lohse CM et al (2012) Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol 19:1153–1159. https://doi.org/10.1245/s10434-011-2084-6
doi: 10.1245/s10434-011-2084-6
pubmed: 21989658
Klauber-DeMore N (2005) Tumor biology of breast cancer in young women. Breast Dis 23:9–15. https://doi.org/10.3233/bd-2006-23103
doi: 10.3233/bd-2006-23103
pubmed: 16823162
He X-M, Zou D-H (2017) The association of young age with local recurrence in women with early-stage breast cancer after breast-conserving therapy: a meta-analysis. Sci Rep 7:11058. https://doi.org/10.1038/s41598-017-10729-9
doi: 10.1038/s41598-017-10729-9
pubmed: 28894168
pmcid: 5593910
Anders CK, Hsu DS, Broadwater G et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330. https://doi.org/10.1200/JCO.2007.14.2471
doi: 10.1200/JCO.2007.14.2471
pubmed: 18612148
Wang J, Tang H, Yin K et al (2021) Second invasive breast cancers in patients treated with breast-conserving therapy. Eur J Surg Oncol 47:2492–2498. https://doi.org/10.1016/j.ejso.2021.06.013
doi: 10.1016/j.ejso.2021.06.013
pubmed: 34134902
Hannoun-Levi J-M, Gutierrez C, Polgar C et al (2021) Letter comments on: The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy. Eur J Cancer 159:224–226. https://doi.org/10.1016/j.ejca.2021.10.008
doi: 10.1016/j.ejca.2021.10.008
pubmed: 34781170
Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953–1958. https://doi.org/10.1093/annonc/mdp263
doi: 10.1093/annonc/mdp263
pubmed: 19596702
pmcid: 2791352
Begg CB, Eng KH, Hummer AJ (2007) Statistical tests for clonality. Biometrics 63:522–530. https://doi.org/10.1111/j.1541-0420.2006.00681.x
doi: 10.1111/j.1541-0420.2006.00681.x
pubmed: 17688504
pmcid: 2736112
Ostrovnaya I, Olshen AB, Seshan VE et al (2010) A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Stat Med 29:1608–1621. https://doi.org/10.1002/sim.3866
doi: 10.1002/sim.3866
pubmed: 20205270
pmcid: 3145177
Minussi DC, Nicholson MD, Ye H et al (2021) Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature 592:302–308. https://doi.org/10.1038/s41586-021-03357-x
doi: 10.1038/s41586-021-03357-x
pubmed: 33762732
pmcid: 8049101
Lips EH, Kumar T, Megalios A et al (2022) Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nat Genet 54:850–860. https://doi.org/10.1038/s41588-022-01082-3
doi: 10.1038/s41588-022-01082-3
pubmed: 35681052
pmcid: 9197769
Rassy E, Garberis I, Tran-Dien A et al (2023) Comparative genomic profiling of second breast cancers following first ipislateral hormone receptor-positive breast cancers. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-2883
doi: 10.1158/1078-0432.CCR-22-2883
pubmed: 36805183
Nilsson MP, Hartman L, Kristoffersson U et al (2014) High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res Treat 147:571–578. https://doi.org/10.1007/s10549-014-3115-3
doi: 10.1007/s10549-014-3115-3
pubmed: 25187270
pmcid: 4174291